These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 12799375)
1. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. Zhao L; Buckman B; Seto M; Morser J; Nagashima M J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375 [TBL] [Abstract][Full Text] [Related]
2. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. Foley JH; Kim P; Nesheim ME J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711 [TBL] [Abstract][Full Text] [Related]
3. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. Schneider M; Nagashima M; Knappe S; Zhao L; Morser J; Nesheim M J Biol Chem; 2002 Mar; 277(12):9944-51. PubMed ID: 11786552 [TBL] [Abstract][Full Text] [Related]
4. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. Zhou X; Declerck PJ J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535 [TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622 [TBL] [Abstract][Full Text] [Related]
6. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693 [TBL] [Abstract][Full Text] [Related]
8. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. Marx PF; Havik SR; Bouma BN; Meijers JC J Thromb Haemost; 2005 Jun; 3(6):1293-300. PubMed ID: 15946220 [TBL] [Abstract][Full Text] [Related]
9. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. Boffa MB; Wang W; Bajzar L; Nesheim ME J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053 [TBL] [Abstract][Full Text] [Related]
10. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497 [TBL] [Abstract][Full Text] [Related]
11. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677 [TBL] [Abstract][Full Text] [Related]
12. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. Marar TT; Boffa MB J Thromb Haemost; 2016 Apr; 14(4):772-83. PubMed ID: 26816270 [TBL] [Abstract][Full Text] [Related]
13. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides. Plug T; Marquart JA; Marx PF; Meijers JC J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360 [TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015 [TBL] [Abstract][Full Text] [Related]
16. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522 [TBL] [Abstract][Full Text] [Related]
18. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. Walker JB; Bajzar L J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744 [TBL] [Abstract][Full Text] [Related]
19. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. Wu C; Kim PY; Manuel R; Seto M; Whitlow M; Nagashima M; Morser J; Gils A; Declerck P; Nesheim ME J Biol Chem; 2009 Mar; 284(11):7059-67. PubMed ID: 19074424 [TBL] [Abstract][Full Text] [Related]